You are now leaving ironwoodpharma.com. This link will take you to
a website to which our privacy policy does not apply. You are solely
responsible for your interactions with that website.

Press Releases

Keyword Search
 
2019 | 2018 | 2017 | 2016 | 2015 | 2014
08.13.19
Ironwood Pharmaceuticals Announces Full Exercise of Convertible Notes Over-Allotment
08.13.19
Ironwood Pharmaceuticals and Alnylam Pharmaceuticals Enter U.S. GI Disease Education and Promotional Agreement for Alnylam’s Givosiran in Acute Hepatic Porphyria (AHP)
08.08.19
Ironwood Pharmaceuticals Announces Pricing of Upsized $350 Million Convertible Senior Notes Offering
08.06.19
Ironwood Pharmaceuticals Announced Proposed Offering of $330 Million of Convertible Senior Notes
07.30.19
Ironwood Pharmaceuticals Reports Second Quarter 2019 Results
07.18.19
Ironwood Pharmaceuticals to Host Second Quarter 2019 Investor Update Call
06.18.19
Ironwood and Allergan Report Positive Topline Data from Phase IIIb Trial of LINZESS® (linaclotide) in Adults with Irritable Bowel Syndrome with Constipation (IBS-C)
06.13.19
Ironwood Pharmaceuticals to Establish New Headquarters in Downtown Boston
06.03.19
Ironwood Pharmaceuticals and Allergan Initiate Patient Dosing in Phase II Clinical Trial of MD-7246 in Patients with Abdominal Pain Associated with IBS-D
05.09.19
Ironwood Pharmaceuticals to Highlight IW-3718 and Linaclotide Data at Digestive Disease Week® 2019
05.07.19
Ironwood Pharmaceuticals to Present at the 2019 Bank of America Merrill Lynch Healthcare Conference
05.02.19
Ironwood Pharmaceuticals Reports First Quarter 2019 Results; Announces Positive 2019 Adjusted EBITDA from Continuing Operations Guidance
04.18.19
Ironwood Pharmaceuticals to Host First Quarter 2019 Investor Update Call
04.16.19
Ironwood Pharmaceuticals Announces Adjustment of Conversion Rate for its 2.25% Convertible Senior Notes due 2020
04.01.19
Ironwood Pharmaceuticals Completes Separation of Cyclerion Therapeutics and Becomes a Gastrointestinal (GI)-focused Healthcare Company
03.14.19
Ironwood Announces Effectiveness of Cyclerion Form 10 Registration Statement
03.07.19
Ironwood Pharmaceuticals to Present at Barclays Global Healthcare Conference
03.04.19
Ironwood Pharmaceuticals to Present at Cowen Health Care Conference
02.26.19
Cyclerion, the Planned R&D Spin-off of Ironwood Pharmaceuticals, Secures Commitments of $175 Million in Private Offering
02.21.19
Ironwood Pharmaceuticals to Present at SVB Leerink Global Healthcare Conference
02.13.19
Ironwood Pharmaceuticals Provides Fourth Quarter and Full Year 2018 Investor Update
01.28.19
Ironwood Pharmaceuticals to Host Fourth Quarter and Full-Year 2018 Investor Update Call
01.28.19
Ironwood Announces Filing of Form 10 Registration Statement in Connection with Planned Business Separation
01.24.19
Ironwood Pharmaceuticals Announces Board of Directors for Ironwood and Cyclerion, Effective Following Separation
01.23.19
Ironwood Pharmaceuticals Initiates Phase 1 Trial of IW-6463, the First CNS-penetrant sGC Stimulator to Enter Clinical Trials
01.15.19
Ironwood Pharmaceuticals Announces Approval of LINZESS® (linaclotide) in China for the Treatment of Adults with IBS-C
01.06.19
Ironwood Pharmaceuticals Appoints Michael Shetzline, M.D., Ph.D. as Chief Medical Officer
01.04.19
Ironwood Pharmaceuticals Announces Chief Executive Officers to Lead Ironwood and Cyclerion, Effective Upon Upcoming Separation
01.02.19
Ironwood Pharmaceuticals to Present at J.P. Morgan Healthcare Conference
01.02.19
Ironwood and Allergan Announce Settlement with Mylan Resolving LINZESS® (linaclotide) Patent Litigation
MEDIA & INVESTOR RELATIONS CONTACT
Meredith Kaya
617.374.5082
mkaya@ironwoodpharma.com


Latest Tweets